Vascular Mimicry

A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Glioblastoma (GBM) is a hypervascular neoplasia of the central nervous system with an extremely high rate of mortality. Owing to its hypervascularity, anti-angiogenic therapies (AAT) have been used as an adjuvant to the traditional surgical resection, chemotherapy, and radiation. The benefits of AAT have been transient and the tumors were shown to relapse faster and demonstrated particularly high rates of AAT therapy resistance. Alternative neovascularization mechanisms were shown to be at work in these resilient tumors to counter the AAT therapy insult. Vascular Mimicry (VM) is the uncanny ability of tumor cells to acquire endothelial-like properties and lay down vascular patterned networks reminiscent of host endothelial blood vessels. The VM channels served as an irrigation system for the tumors to meet with the increasing metabolic and nutrient demands of the tumor in the event of the ensuing hypoxia resulting from AAT. In our previous studies, we have demonstrated that AAT accelerates VM in GBM. In this review, we will focus on the origins of VM, visualizing VM in AAT-treated tumors and the development of VM as a resistance mechanism to AAT.

Original languageEnglish (US)
Pages (from-to)650-660
Number of pages11
JournalTranslational Oncology
Volume10
Issue number4
DOIs
StatePublished - Aug 1 2017

Fingerprint

Glioblastoma
Blood Vessels
Neoplasms
Therapeutics
Central Nervous System
Radiation
Recurrence
Drug Therapy
Food
Mortality

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Vascular Mimicry : A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma. / Angara, Kartik; Borin, Thaiz Ferraz; Arbab, Ali Syed.

In: Translational Oncology, Vol. 10, No. 4, 01.08.2017, p. 650-660.

Research output: Contribution to journalReview article

@article{f28c9a9bf7b44364a878e5db8c48c524,
title = "Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma",
abstract = "Glioblastoma (GBM) is a hypervascular neoplasia of the central nervous system with an extremely high rate of mortality. Owing to its hypervascularity, anti-angiogenic therapies (AAT) have been used as an adjuvant to the traditional surgical resection, chemotherapy, and radiation. The benefits of AAT have been transient and the tumors were shown to relapse faster and demonstrated particularly high rates of AAT therapy resistance. Alternative neovascularization mechanisms were shown to be at work in these resilient tumors to counter the AAT therapy insult. Vascular Mimicry (VM) is the uncanny ability of tumor cells to acquire endothelial-like properties and lay down vascular patterned networks reminiscent of host endothelial blood vessels. The VM channels served as an irrigation system for the tumors to meet with the increasing metabolic and nutrient demands of the tumor in the event of the ensuing hypoxia resulting from AAT. In our previous studies, we have demonstrated that AAT accelerates VM in GBM. In this review, we will focus on the origins of VM, visualizing VM in AAT-treated tumors and the development of VM as a resistance mechanism to AAT.",
author = "Kartik Angara and Borin, {Thaiz Ferraz} and Arbab, {Ali Syed}",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.tranon.2017.04.007",
language = "English (US)",
volume = "10",
pages = "650--660",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "4",

}

TY - JOUR

T1 - Vascular Mimicry

T2 - A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma

AU - Angara, Kartik

AU - Borin, Thaiz Ferraz

AU - Arbab, Ali Syed

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Glioblastoma (GBM) is a hypervascular neoplasia of the central nervous system with an extremely high rate of mortality. Owing to its hypervascularity, anti-angiogenic therapies (AAT) have been used as an adjuvant to the traditional surgical resection, chemotherapy, and radiation. The benefits of AAT have been transient and the tumors were shown to relapse faster and demonstrated particularly high rates of AAT therapy resistance. Alternative neovascularization mechanisms were shown to be at work in these resilient tumors to counter the AAT therapy insult. Vascular Mimicry (VM) is the uncanny ability of tumor cells to acquire endothelial-like properties and lay down vascular patterned networks reminiscent of host endothelial blood vessels. The VM channels served as an irrigation system for the tumors to meet with the increasing metabolic and nutrient demands of the tumor in the event of the ensuing hypoxia resulting from AAT. In our previous studies, we have demonstrated that AAT accelerates VM in GBM. In this review, we will focus on the origins of VM, visualizing VM in AAT-treated tumors and the development of VM as a resistance mechanism to AAT.

AB - Glioblastoma (GBM) is a hypervascular neoplasia of the central nervous system with an extremely high rate of mortality. Owing to its hypervascularity, anti-angiogenic therapies (AAT) have been used as an adjuvant to the traditional surgical resection, chemotherapy, and radiation. The benefits of AAT have been transient and the tumors were shown to relapse faster and demonstrated particularly high rates of AAT therapy resistance. Alternative neovascularization mechanisms were shown to be at work in these resilient tumors to counter the AAT therapy insult. Vascular Mimicry (VM) is the uncanny ability of tumor cells to acquire endothelial-like properties and lay down vascular patterned networks reminiscent of host endothelial blood vessels. The VM channels served as an irrigation system for the tumors to meet with the increasing metabolic and nutrient demands of the tumor in the event of the ensuing hypoxia resulting from AAT. In our previous studies, we have demonstrated that AAT accelerates VM in GBM. In this review, we will focus on the origins of VM, visualizing VM in AAT-treated tumors and the development of VM as a resistance mechanism to AAT.

UR - http://www.scopus.com/inward/record.url?scp=85026923143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026923143&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2017.04.007

DO - 10.1016/j.tranon.2017.04.007

M3 - Review article

VL - 10

SP - 650

EP - 660

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 4

ER -